---
aliases: [AMGN]
---
#actor #biotech #biosimilars #usa #public

**Amgen** — Large-cap biotech. MariTide obesity challenger. $3B+ biosimilars. 14 potential blockbusters.

---

## Why Amgen matters

| Metric | Value |
|--------|-------|
| Ticker | AMGN ([[Nasdaq]]) |
| 2024 revenue growth | +22% |
| Q1 2025 revenue | $8.15B (+9%) |
| Biosimilars | **$3B** annualized |
| Blockbuster candidates | 14 products |

---

## MariTide (Obesity)

| Metric | Value |
|--------|-------|
| Dosing | **Monthly** (vs weekly competitors) |
| Weight loss | Up to ~20% (Phase 2) |
| Phase 3 | 5 studies started H1 2025 |
| Peak sales est | $3.7B (2030) |

**Differentiation:** First monthly or less frequent dosing in obesity.

**Concerns:** Phase 2 full results disappointed — dropout rates, GI side effects.

---

## Biosimilars portfolio

| Product | [[Target]] | Status |
|---------|--------|--------|
| Wezlana | Stelara | Ramping |
| Pavblu | Eylea | Launched |
| Bekemv | Soliris | Growing |

**Revenue:** ~$3B annualized (9% of Q1 2025 revenue).
**[[Target]]:** $4B+ by 2030.

---

## Key products

| Product | Indication |
|---------|------------|
| Enbrel | Autoimmune |
| Prolia/Xgeva | Bone health |
| Repatha | Cholesterol |
| Lumakras | Oncology |
| Horizon assets | Rare disease |

**LOE risk:** Prolia/Xgeva patents expired early 2025.

---

## Challenges

| Issue | Impact |
|-------|--------|
| Prolia/Xgeva LOE | Biosimilar erosion |
| MariTide uncertainty | Phase 2 disappointed |
| Growth slowdown | 2026 low-single-digit expected |
| Competition | GLP-1 market crowded |

---

## TCJA repatriation (2018)

Amgen repatriated significant overseas cash under the [[Tax Cuts and Jobs Act]] one-time tax holiday. Deployed primarily into buybacks.

---

## Investment case

**Bull:**
- MariTide monthly dosing advantage
- Biosimilars growth to $4B+
- Diversified 14-product portfolio
- Horizon acquisition synergies

**Bear:**
- MariTide data underwhelmed
- Prolia/Xgeva erosion accelerating
- Growth slowing to low-single-digit
- Late to obesity market

---


![[amgn-employees-chart.png]]
*Headcount: 31,500 (2025) — up 12.5% YoY*

## Quick stats

| Metric | Value |
|--------|-------|
| Ticker | AMGN |
| Exchange | [[Nasdaq]] |
| Revenue | ~$33B |
| Focus | Biotech, biosimilars, obesity |

---

## Related

- [[Novo Nordisk]] — GLP-1 leader
- [[Eli Lilly]] — GLP-1 competitor
- [[Biopharma]] — sector
- [[Tax Cuts and Jobs Act]] — repatriation (2018)

---

## Sources

- [Amgen investor relations](https://investors.amgen.com/)
- [BioSpace: Portfolio play](https://www.biospace.com/business/beyond-maritide-amgen-makes-portfolio-play-amid-scrutiny-of-obesity-prospect)

*Created 2026-01-09*
